AVN 66.90 Increased By ▲ 2.05 (3.16%)
BOP 8.85 Increased By ▲ 0.15 (1.72%)
CHCC 133.00 Increased By ▲ 8.79 (7.08%)
DCL 9.31 Increased By ▲ 0.41 (4.61%)
DGKC 104.60 Increased By ▲ 3.71 (3.68%)
EFERT 61.60 No Change ▼ 0.00 (0%)
EPCL 44.52 Increased By ▲ 1.52 (3.53%)
FCCL 20.80 Increased By ▲ 0.40 (1.96%)
FFL 14.32 Increased By ▲ 0.50 (3.62%)
HASCOL 14.11 Increased By ▲ 0.54 (3.98%)
HBL 129.52 Increased By ▲ 0.70 (0.54%)
HUBC 79.90 Increased By ▲ 1.40 (1.78%)
HUMNL 6.47 Decreased By ▼ -0.03 (-0.46%)
JSCL 23.26 Increased By ▲ 0.96 (4.3%)
KAPCO 28.30 Increased By ▲ 0.67 (2.42%)
KEL 3.73 Increased By ▲ 0.12 (3.32%)
LOTCHEM 12.69 Increased By ▲ 0.22 (1.76%)
MLCF 38.47 Increased By ▲ 1.95 (5.34%)
OGDC 102.64 Increased By ▲ 5.11 (5.24%)
PAEL 32.35 Increased By ▲ 1.50 (4.86%)
PIBTL 12.15 Increased By ▲ 0.28 (2.36%)
PIOC 90.33 Increased By ▲ 6.83 (8.18%)
POWER 9.57 Increased By ▲ 0.40 (4.36%)
PPL 93.48 Increased By ▲ 5.56 (6.32%)
PSO 195.43 Increased By ▲ 5.15 (2.71%)
SNGP 43.25 Increased By ▲ 0.51 (1.19%)
STPL 13.39 Increased By ▲ 0.14 (1.06%)
TRG 57.82 Increased By ▲ 4.92 (9.3%)
UNITY 23.45 Decreased By ▼ -0.17 (-0.72%)
WTL 1.03 Increased By ▲ 0.03 (3%)
BR100 4,268 Increased By ▲ 73.36 (1.75%)
BR30 21,484 Increased By ▲ 395.94 (1.88%)
KSE100 41,064 Increased By ▲ 686.2 (1.7%)
KSE30 17,329 Increased By ▲ 312.82 (1.84%)

Abbott Laboratories beat analysts' estimates for quarterly profit on Wednesday and raised its full-year adjusted earnings forecast, driven by demand for its FreeStyle Libre blood sugar monitoring device.

Sales of FreeStyle Libre, which helps diabetics track their blood sugar levels without having to prick their fingers, surged 63.9% to $433 million in the second quarter.

The company plans to boost manufacturing capacity for Libre, its fastest-growing diabetes product by three to five times in the next few years as it aims to reach millions more patients worldwide, a company executive told Reuters on Tuesday.

The surge in demand for the diabetes device helped Abbott's medical devices unit, which also houses its heart devices business, report a 6.4% rise in sales to $3.08 billion.

Abbott also raised its full-year 2019 adjusted earning from continuing operations forecast to $3.21 to $3.27 per share, from its prior forecast of $3.15 to $3.25 per share.

The company's net earnings rose to $1 billion, or 56 cents per share, in the second quarter ended June 30, from $733 million, or 41 cents per share, a year earlier.

Excluding items, Abbott earned 82 cents per share, ahead of the average analyst estimate of 80 cents, according to IBES data from Refinitiv.

Net sales of the company, whose products include infant nutritional formula, rose 2.7% to $7.98 billion, but missed estimates of $8 billion.

Copyright Reuters, 2019